Adagene Inc. (ADAG)Healthcare | Biotechnology | Suzhou, China | NasdaqGM
3.68 USD
-0.22
(-5.641%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 3.68 |
Hot Take ↕ | Aug. 22, 2026, 4:15 a.m. EDT
The immediate outlook remains neutral due to conflicting signals: while the stock recently rallied off its lows, the underlying business fundamentals are severely deteriorating. The company is burning significant cash with negative operating and free cash flows, and the balance sheet shows a concerning debt-to-equity ratio despite holding some cash. Crucially, the multi-year price trajectory reveals a catastrophic decline of over 85%, driven by three consecutive years of negative annual returns, which suggests the market has permanently reassessed the business quality. Although analysts offer a 'strong buy' recommendation with a high target price, this appears to be a speculative bet on a potential turnaround rather than a reflection of current operational reality. With no dividend history and a history of massive losses, there is no safety net for investors. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.089251 |
| MSTL | 0.092137 |
| AutoETS | 0.096413 |
| AutoARIMA | 0.096414 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 39% |
| H-stat | 0.92 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.375 |
| Excess Kurtosis | 0.08 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 5.746 |
| Revenue per Share | 0.179 |
| Market Cap | 247,087,504 |
| Forward P/E | -6.57 |
| Beta | 0.57 |
| Profit Margins | -220.77% |
| Website | https://www.adagene.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 0.8396226 |
| Address1 | Building C14 |
| Address2 | 4th Floor No. 218, Xinghu Street Suzhou Industrial Park |
| All Time High | 31.83 |
| All Time Low | 0.9 |
| Ask | 4.0 |
| Ask Size | 3 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 272,280 |
| Average Daily Volume3 Month | 269,662 |
| Average Volume | 269,662 |
| Average Volume10Days | 272,280 |
| Beta | 0.572 |
| Bid | 2.56 |
| Bid Size | 2 |
| Book Value | 1.332 |
| City | Suzhou |
| Country | China |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 3.68 |
| Current Ratio | 5.023 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 3.8672 |
| Day Low | 3.66 |
| Debt To Equity | 5.746 |
| Display Name | Adagene |
| Earnings Timestamp End | 1,753,704,000 |
| Earnings Timestamp Start | 1,753,268,340 |
| Ebitda | -21,952,354 |
| Ebitda Margins | -2.3628 |
| Enterprise To Ebitda | -6.46 |
| Enterprise To Revenue | 15.264 |
| Enterprise Value | 141,818,704 |
| Eps Current Year | -0.52 |
| Eps Forward | -0.56 |
| Eps Trailing Twelve Months | -0.37 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 3.873 |
| Fifty Day Average Change | -0.19299984 |
| Fifty Day Average Change Percent | -0.04983213 |
| Fifty Two Week Change Percent | 83.962265 |
| Fifty Two Week High | 4.85 |
| Fifty Two Week High Change | -1.1699998 |
| Fifty Two Week High Change Percent | -0.24123709 |
| Fifty Two Week Low | 1.3 |
| Fifty Two Week Low Change | 2.38 |
| Fifty Two Week Low Change Percent | 1.8307694 |
| Fifty Two Week Range | 1.3 - 4.85 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,612,881,000,000 |
| Float Shares | 42,170,720 |
| Forward Eps | -0.56 |
| Forward P E | -6.571429 |
| Free Cashflow | -12,158,853 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 128 |
| Fullday Change | -0.22 |
| Fullday Change Percent | -5.64103 |
| Fullday Price | 3.68 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 1.0 |
| Gross Profits | 9,290,815 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.21292 |
| Held Percent Institutions | 0.35937 |
| Implied Shares Outstanding | 67,143,344 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-02-09 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development. In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors. Adagene Inc. was incorporated in 2011 and is headquartered in Suzhou, China. |
| Long Name | Adagene Inc. |
| Market | us_market |
| Market Cap | 247,087,504 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_118162960 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -20,511,004 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 262,530,475 |
| Number Of Analyst Opinions | 6 |
| Open | 3.86 |
| Operating Cashflow | -19,247,964 |
| Operating Margins | -10.23915 |
| Payout Ratio | 0.0 |
| Phone | 86 512 8777 3632 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 3.68 |
| Post Market Time | 1,787,959,804 |
| Previous Close | 3.9 |
| Price Eps Current Year | -7.0769234 |
| Price Hint | 4 |
| Price To Book | 2.7627628 |
| Price To Sales Trailing12 Months | 26.594814 |
| Profit Margins | -2.20766 |
| Quick Ratio | 4.858 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.28571 |
| Region | US |
| Regular Market Change | -0.22 |
| Regular Market Change Percent | -5.64103 |
| Regular Market Day High | 3.8672 |
| Regular Market Day Low | 3.66 |
| Regular Market Day Range | 3.66 - 3.8672 |
| Regular Market Open | 3.86 |
| Regular Market Previous Close | 3.9 |
| Regular Market Price | 3.68 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 123,153 |
| Return On Assets | -0.13954 |
| Return On Equity | -0.28504 |
| Revenue Per Share | 0.179 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 67,143,344 |
| Shares Percent Shares Out | 0.031400003 |
| Shares Short | 2,110,754 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 2,189,615 |
| Short Name | Adagene Inc. |
| Short Percent Of Float | 0.0369 |
| Short Ratio | 9.49 |
| Source Interval | 15 |
| Symbol | ADAG |
| Target High Price | 17.45 |
| Target Low Price | 7.0 |
| Target Mean Price | 10.74167 |
| Target Median Price | 9.0 |
| Total Cash | 127,909,840 |
| Total Cash Per Share | 1.905 |
| Total Debt | 6,091,037 |
| Total Revenue | 9,290,815 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.37 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 3.170735 |
| Two Hundred Day Average Change | 0.5092652 |
| Two Hundred Day Average Change Percent | 0.16061424 |
| Type Disp | Equity |
| Volume | 123,153 |
| Website | https://www.adagene.com |
| Zip | 215,123 |